Qiagen N.V. (NYSE:QGEN) Receives Consensus Recommendation of “Hold” from Analysts

Qiagen N.V. (NYSE:QGEN) has been given a consensus rating of “Hold” by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $49.6944.

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays set a $53.00 target price on shares of Qiagen and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday, October 8th. UBS Group boosted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Cowen reissued a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th.

Qiagen Trading Down 3.4%

Shares of NYSE QGEN opened at $44.13 on Wednesday. The firm has a 50 day moving average price of $46.66 and a two-hundred day moving average price of $46.48. The stock has a market cap of $9.81 billion, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. Qiagen has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.03. The company had revenue of $533.00 million for the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. Qiagen’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.57 earnings per share. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. As a group, equities analysts forecast that Qiagen will post 2.26 EPS for the current year.

Institutional Trading of Qiagen

Large investors have recently modified their holdings of the stock. Allianz Asset Management GmbH lifted its holdings in shares of Qiagen by 53.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,529,224 shares of the company’s stock worth $68,028,000 after purchasing an additional 534,527 shares in the last quarter. Callan Family Office LLC lifted its stake in shares of Qiagen by 27.5% in the third quarter. Callan Family Office LLC now owns 8,063 shares of the company’s stock valued at $360,000 after buying an additional 1,741 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Qiagen by 64.0% during the third quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock valued at $71,000 after buying an additional 628 shares during the last quarter. State of Wyoming increased its position in shares of Qiagen by 188.2% during the third quarter. State of Wyoming now owns 11,813 shares of the company’s stock worth $528,000 after acquiring an additional 7,714 shares in the last quarter. Finally, Lingohr Asset Management GmbH acquired a new stake in shares of Qiagen in the 3rd quarter worth about $4,218,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.